BMP10: A Potential Drug Target for Various Diseases (G27302)

Target Name: BMP10

NCBI ID: G27302

BMP10

Other Name(s): BMP10_HUMAN | bone morphogenetic protein 10 | BMP-10 | Bone morphogenetic protein 10 | Bone morphogenetic protein 10 preproprotein

BMP10: A Potential Drug Target for Various Diseases

The B-cell maturation antigen (BMP) is a key regulator of hematopoietic stem cell (HSC) proliferation and differentiation, and is involved in the development of many diseases, including cancer. BMP signaling has been extensively studied, and several BMP inhibitors have been developed as potential therapeutic approaches. One of these inhibitors, BMP10 (BMP10_HUMAN), has shown promise in preclinical studies and is currently being targeted by researchers as a drug target for the treatment of various diseases.

BMP10 is a 24kDa transmembrane protein that is expressed in a variety of tissues, including bone marrow, peripheral blood, and various organs. It is a potent regulator of HSC proliferation and differentiation, and has been shown to induce the expression of many genes involved in cell growth, survival, and angiogenesis. BMP10 has also been shown to play a role in the regulation of immune cell function, and has been shown to enhance the immune response against cancer cells.

Despite the promising preclinical results, much work remains to be done before BMP10 can be approved as a drug. Understanding the molecular mechanisms underlying BMP10's activity is an important step in the development of new treatments for various diseases.

BMP10 signaling

BMP10 is involved in the regulation of multiple cellular processes, including cell growth, survival, and angiogenesis. Its signaling pathway is complex and involves several different signaling pathways.

One of the well-established signaling pathways associated with BMP10 is the TGF-β pathway. TGF-β is a cytoplasmic protein that is involved in the regulation of cell growth, survival, and angiogenesis. TGF-β signaling is activated by a variety of factors, including BMP10. When BMP10 is expressed in cells, it can induce the expression of TGF-β genes, including BMP10 itself. This increase in TGF-β activity can lead to increased cell proliferation, survival, and angiogenesis.

Another signaling pathway associated with BMP10 is the NF-kappa-B pathway. NF-kappa-B is a protein that is involved in the regulation of inflammation, cell survival, and angiogenesis. BMP10 has been shown to induce the expression of NF-kappa-B genes, which can lead to increased inflammation and cell survival.

BMP10's effects on cancer cells

BMP10 has been shown to play a role in the regulation of cancer cell growth and survival. Several studies have shown that BMP10 can inhibit the growth of various cancer cell types, including breast, lung, and colorectal cancer cells. This inhibition of cell growth and survival may be due to the anti-inflammatory and anti-tumor effects of BMP10.

Additionally, BMP10 has been shown to enhance the sensitivity of cancer cells to chemotherapy. This may be due to the increased angiogenesis that occurs in response to BMP10, which can cause cancer cells to receive less oxygen and nutrients and are more susceptible to chemotherapy.

BMP10's effects on immune cells

BMP10 has also been shown to play a role in the regulation of immune cell function. BMP10 has been shown to enhance the production of immune cells, such as natural killer cells and T-cells, and to increase their ability to recognize and respond to cancer cells. This may be due to the increased angiogenesis that occurs in response to BMP10, which can provide a source of nutrients and oxygen for immune cells.

BMP10's potential as a drug target

BMP10's ability to regulate multiple cellular processes makes it an attractive target for the development of new drugs for various diseases. Preclinical studies have shown that BMP10 can be effectively inhibited using a variety of techniques, including inhibitors of its downstream signaling pathways

Protein Name: Bone Morphogenetic Protein 10

Functions: Required for maintaining the proliferative activity of embryonic cardiomyocytes by preventing premature activation of the negative cell cycle regulator CDKN1C/p57KIP and maintaining the required expression levels of cardiogenic factors such as MEF2C and NKX2-5. Acts as a ligand for ACVRL1/ALK1, BMPR1A/ALK3 and BMPR1B/ALK6, leading to activation of SMAD1, SMAD5 and SMAD8 transcription factors. Inhibits endothelial cell migration and growth. May reduce cell migration and cell matrix adhesion in breast cancer cell lines

The "BMP10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BMP10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets